Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03057028 · ClinicalTrials.gov registry record · Phase 1
Pilot Study of the Safety and Efficacy of Anakinra in Pulmonary Arterial Hypertension
A Phase 1 study, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT03057028 is a Phase 1 study that has completed, run by Virginia Commonwealth University. The registered enrollment target is 7 participants.
The verdict
NCT03057028, a Phase 1 study, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
Pulmonary arterial hypertension (PAH) can result in right ventricular failure and death. Anakinra has been used in patients with left sided heart failure, and the present study looks to determine if anakinra is safe and effective in patients with PAH. To accomplish this goal, we plan to evaluate for exercise improvement (as assessed by cardiopulmonary exercise testing) in 10 patients with PAH on anakinra.
Interventions
- DRUG Anakinra
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2016-04 |
| Est. Completion | 2018-06-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03057028
The ClinicalTrials.gov registry entry for NCT03057028 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Anakinra is the first listed.
NCT03057028 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03057028 about?
NCT03057028 is a clinical study titled "Pilot Study of the Safety and Efficacy of Anakinra in Pulmonary Arterial Hypertension". Pulmonary arterial hypertension (PAH) can result in right ventricular failure and death. Anakinra has been used in patients with left sided heart failure, and the present study looks to determine if anakinra is safe and effective in patients with PAH. To accomplish this goal, we plan to evaluate for...
What is the current status of trial NCT03057028?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2016-04. Estimated completion is 2018-06-07.
What interventions are being tested in trial NCT03057028?
The interventions under investigation include: Anakinra (DRUG).
Who is sponsoring clinical trial NCT03057028?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.